Clinical Trial Update: Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating QAW039 added to standard-of-care therapy in patients with uncontrolled asthma completed. Results were posted in February 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• QAW039

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2020-02-28